Connect with us

Market News

RETA Stock Price At 100.07: Here’s All You Need To Know

Published

on

Reata Pharmaceuticals, Inc. (NASDAQ: RETA)’s stock price increased by 13.19% as of April 26’21, 4PM EDT Market close. The closing price of April 26 was 100.07, showing a surge of 11.66 over the previous closing price of 88.41. The volume was 537,653 and the day’s range was between 84.17 – 186.82. 

Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is a clinical-stage biopharmaceutical company whose stock’s pre-market price stands at 102.02  as of 6:15AM EDT, Apri 27. A surge of 1.95 is observable. April 26’s highest price was 101.48 and the lowest price was 90.21. 

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) accepted for filing the New Drug Application (“NDA”) for bardoxolone methyl (“bardoxolone”) for the treatment of patients with chronic kidney disease (“CKD”) caused by Alport syndrome.

This NDA submission is based on the efficacy and safety data from the CARDINAL Phase 3 clinical trial. The FDA will review the application under a Standard Review timeline. The Prescription Drug User Fee Act (“PDUFA”) date, the FDA action date for the application, is scheduled for February 25, 2022. The FDA also advised the Company that it is currently planning to hold an Advisory Committee meeting to discuss the application.

“We are pleased with the FDA’s decision to accept filing our NDA for bardoxolone and look forward to continuing to work with the Division during the review process,” said Warren Huff, Reata’s President and Chief Executive Officer. “Alport syndrome is one of the most rapidly progressive forms of CKD and a truly devastating disease to those patients and the families who are affected by it. If approved, bardoxolone may be the first therapy to slow the progression of kidney disease in patients with this serious and debilitating disease.”

The CARDINAL Phase 3 study was a double-blind, placebo-controlled, randomized trial that enrolled 157 patients with CKD caused by Alport syndrome at approximately 50 study sites in the United States, Europe, Japan, and Australia. Patients were randomized 1:1 to once-daily, oral bardoxolone or placebo. The primary endpoint for Year 2 of the study was the change from baseline in eGFR after 100 weeks of treatment. The key secondary endpoint for Year 2 of the study was the change from baseline in eGFR at Week 104 (four weeks after the last dose in the second year of treatment). Results from CARDINAL demonstrated that patients treated with bardoxolone experienced a statistically significant improvement in kidney function as measured by eGFR at Week 100 and Week 104, compared to patients treated with placebo. Bardoxolone was generally reported to be well tolerated in this study, and the safety profile was similar to that observed in prior trials. The reported adverse events (“AE”) were generally mild to moderate in intensity, and the most common AEs observed more frequently in patients treated with bardoxolone compared to patients treated with placebo were muscle spasms and increases in aminotransferases.

Bardoxolone is an investigational, once-daily, orally administered activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The FDA has granted Orphan Drug designation to bardoxolone for the treatment of Alport syndrome and autosomal dominant polycystic kidney disease (“ADPKD”). The European Commission has granted Orphan Drug designation in Europe to bardoxolone for the treatment of Alport syndrome.

In addition to the CARDINAL Phase 3 study, bardoxolone is currently being studied in FALCON, a Phase 3 study for the treatment of ADPKD, MERLIN, a Phase 2 study for the treatment of patients with CKD at risk of rapid progression, and AYAME, a Phase 3 study for the treatment of diabetic kidney disease that is being conducted by our licensee, Kyowa Kirin Co., Ltd., in Japan. Bardoxolone treatment has produced positive results in Phase 2 studies in patients with CKD caused by ADPKD, IgA nephropathy, focal segmental glomerulosclerosis, and type 1 diabetes.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Market News

Top 5 Stock Price Gainers of May 17: US Stock Market

Published

on

Consumer Automotive Finance, Inc. (OTCMKTS: NWAU)

Consumer Automotive Finance, Inc. (OTCMKTS: NWAU)’s stock price increased by 22.50%. The closing price as of May 16 was $0.0400, over which, the price increased by $0.0090 on May 17. The closing price as of May 17 stands at $0.0490. The opening price was $0.0625, the range was 0.0400 – 0.0625 and the volume was 199,804. 

 

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)

The stock price of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stands at $53.60 as of May 17. The price shows a growth of $8.80(19.88%) over the previous ( May 16) closing price of $44.26.  The opening price as of May 17 was $49.01; the day’s range was 48.96 – 54.25. The volume was above average, being 6,234,624.

 

Globalstar, Inc. (NYSE: GSAT)

Globalstar, Inc. (NYSE: GSAT)’s closing stock as of May 17 stands at $1.3600. The price shows a growth of $0.2200 (19.30%) over the previous ( May 16) closing price of $1.1400. May 17’s opening price was $1.1000 and the day’s range was 1.1000 – 1.3800. The volume was 24,374,234, slightly above average. 

 

Hecla Mining Company (NYSE: HL)

Hecla Mining Company (NYSE: HL)’s stock price increased by a huge amount of 16.53%. The previous price, i.e, May 16’s price was $7.56. The current price as of May 17, is $8.81 which is $1.25 more than the previous closing price. The opening price of May 17 was $7.73. The price range for the day was 7.65 – 8.88; the volume was 23,888,169.

 

Discovery, Inc. (NASDAQ: DISCB)

$80.18 is the current( as of May 17) stock price of Discovery, Inc. (NASDAQ: DISCB). The price shows a growth of $9.67 (13.71%) over the previous (May 16) closing price of $70.51.  The pre-market price as of  4:04AM EDT, May 18 remains the same as the closing price of May 17, $80.18 .

Continue Reading

Market News

TOP STOCKS GAINERS FOR MAY 12

Published

on

AbCellera Biologics Inc. (NASDAQ: ABCL)

AbCellera Biologics Inc. (NASDAQ: ABCL)’s stock price increased by 8.74% over the previous closing price of $28.25. The price, as of May 12 closing price, is $30.72. The Pre-market price is stagnant as of 4:59 AM EDT, May 13. 

 

UWM Holdings Corporation Class (NYSE: UWMC) 

UWM Holdings Corporation Class (NYSE: UWMC)’s stock price increased by 8.96% on May 12. May 12’s closing price was $0.59 more than the previous ( May 11) closing price of $6.79. The opening price of May 12 was $6.74; the range was 6.70 – 7.61 and the volume was 9,919,270. However, the Pre-market price says a different story. The price has dropped, as of 5:35 AM EDT by 3.12% and currently stands at $7.15.

 

CVR Energy, Inc. (NYSE: CVI)

CVR Energy, Inc. (NYSE: CVI)’ stock price as of May 12 was $22.77, which is $1.79 more than the previous closing price of $20.98. The day’s range was  22.02-23.90 and the volume was 1,595,046. The opening price as of May 12 was $22.96.

 

Intercorp Financial Services Inc. (NYSE: IFS)

Intercorp Financial Services Inc. (NYSE: IFS)’s stock price increased by 11.31%. The closing price as of May 12 was $29.43, which is $2.26(8.32%) more than the previous closing price of $27.17. The volume was 82,164 and the range was 27.16 – 29.86. The opening price of May 12  was $25.14. 

 

Pershing Square Tontine Holdings, Ltd. (NYSE: PSTH)

Pershing Square Tontine Holdings, Ltd. (NYSE: PSTH)’ stock price increased by a good amount of 7.33%. The closing price as of May 12 was $24.38, which is $1.75 more than the previous closing price of  $22.63. The price has dropped as of 5:17 AM EDT, May 13, Pre-market, and stands at $24.22. 

Continue Reading

Market News

TOP STOCK Market Gainers: LTCN, HL, GCPEF, ABEV, RUN

Published

on

Grayscale Litecoin Trust (OTCMKTS: LTCN)

Grayscale Litecoin Trust’s (OTCMKTS: LTCN) closing price as of May 6 was $445.99. The price hike was recorded to be 17.67%, more than the previous closing price of $379.03. The opening price was $396.00, the volume was 45,765 and the range was 379.05 – 452.12 and respectively. 

Hecla Mining Company (NYSE: HL)

Hecla Mining Company’s (NYSE: HL) closing stock price as of May 6 was $7.29. This showed a growth of 16.64% over the previous closing price of $6.25. The opening price was $6.41, with the volume being 24,884,791 and the day’s range being 6.41 – 7.32. 

GCL-Poly Energy Holdings Limited (OTCMKTS: GCPEF)

GCL-Poly Energy Holdings Limited’s (OTCMKTS: GCPEF) stock price increased by 13.33% over the previous( May 5) closing price of $0.2250. The opening price of May 6 was $0.2400. The volume was 196,480 and the day’s range was 0.2300 – 0.2600.

Ambev S.A. (NYSE: ABEV)

Ambev S.A. (NYSE: ABEV) stock price increased to $3.1200(closing price, May 6) from $2.7900(closing price, May 5). The growth percentage was recorded to be 11.83%. The opening price of May 6 was 3.0600, the volume being 62,369,302 and the range being 2.9800 – 3.1200. 

Sunrun Inc. (NASDAQ: RUN)

Sunrun Inc. (NASDAQ: RUN) stock price increased by 11.69% over the previous closing price( May 5) of $41.84. The closing price of May 6 was sighted to be $46.73. The opening price of May 6-  44.80, volume- 15,073,385 and the range- 43.29 – 46.97.

Continue Reading

Trending